Media Room

Welcome, and thank you for accessing our Media Room, which is your gateway to relevant information about the HIV Vaccine Trials Network (HVTN).  We are a team of people on a scientific journey to find an effective preventive HIV vaccine.  Our work is made possible through the commitment of our heroes – individuals, families, and communities around the world who contribute to the success and impact of our work.

Recent Press Releases

APRIL 1, 2020 – Public statement by the HIV Vaccine Trials Network (HVTN) on Covid-19

The HVTN continues to monitor the impact of COVID-19 on the conduct of the early and large-scale clinical trials we coordinate globally.  We remain committed to the safety and wellbeing of all study participants and study teams. Read more >


APRIL 1, 2020 – The HVTN and HPTN Remember Gita Ramjee

Gita Ramjee, PhD, renowned for her extensive work on HIV prevention and a valued colleague to so many in the HIV Vaccine and Prevention Trials Networks (HVTN and HPTN), sadly succumbed to complications associated with SARS-CoV-2 infection.


MARCH 23, 2020 – Public statement by the HIV Vaccine Trials Network (HVTN) on Covid-19

The COVID-19 pandemic is evolving rapidly and impacting each country and community differently. The leadership of the HVTN, in consideration of the impact of COVID-19, is committed to ensuring the safety and welfare of all study participants and study teams making the early phase and large-scale clinical trials coordinated by the Network possible. Read more >


SEATTLE, OCTOBER 31, 2019 – HVTN study confirms correlates of risk associated with decrease in HIV transmission

Immune responses that are associated with a decreased risk of infection are called correlates of protection (CoP). Clinical trials that measure vaccine-induced antibody and cell-mediated immune responses help to define CoP to HIV, which are necessary to assess the efficacy of a promising HIV vaccine candidate. Read more >


SEATTLE, OCTOBER 01, 2019 – HVTN study demonstrates anti-HIV antibody responses within 6 weeks of initial HIV vaccination

An early phase study was conducted in the U.S. in which different combinations of DNA (DNA-HIV-PT123) and protein (AIDSVAX® B/E) vaccines were administered in four randomized treatment groups (T1, T2, T3, T4), to determine which strategy would induce favorable HIV-specific antibody and T-cell responses. Read more >


SEATTLE, SEPTEMBER 18, 2019 –  Cross clade vaccine induced immune responses found in South Africa from the RV144/Thai HIV vaccine regimen

The results of the study called HVTN 097, titled “Immune correlates of the Thai RV144 vaccine regimen in South Africa” and led by Dr. Glenda Gray, Co-Principal Investigator of the HIV Vaccine Trials Network (HVTN), headquartered at the Fred Hutchinson Cancer Research Center and funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and President of the South African Medical Research Council (SAMRC), were published in the journal Science Translational Medicine on September 18. This study was conducted in South Africa using the same HIV vaccine regimen that showed modest protection in an efficacy study conducted in Thailand, where clades B and E are prominent. Although clade C is the dominant circulating strain of HIV in South Africa, the RV144/Thai vaccine regimen mounted significant cellular and antibody responses in study participants enrolled in South Africa. Read more >


SEATTLE, JULY 15, 2019 – HVTN joins new public-private partnership; expands scientific journey for a safe and effective HIV vaccine

Approximately 55 clinical research sites in South America, the U.S. and Europe, are geared to participate in a new large-scale HIV vaccine efficacy clinical trial, called Mosaico (HVTN 706/HPX3002).  At the upcoming 10th IAS Conference on HIV Science (IAS 2019) taking place July 21-24 in Mexico City, the HIV Vaccine Trials Network, headquartered at Fred Hutchinson Cancer Research Center, and a global consortium of partners will describe how the next candidate preventive HIV vaccine regimen will move forward in a clinical trial to test its efficacy among cisgender men and transgender people who have sex with men. Read more >


SEATTLE, JUNE 21,2019 – HVTN’s large-scale HIV vaccine efficacy trials fully enrolled

The HIV Vaccine Trials Network (HVTN), headquartered at the Fred Hutchinson Cancer Research Center, has fully enrolled its four ongoing large-scale HIV vaccine efficacy trials. . The clinical trials, underway on four continents in 12 countries, are made possible by 12,669 study participants and the collaborative efforts of HVTN study teams, all on a journey to find a safe and effective HIV vaccine. Read more >


SEATTLE, – JUNE 18, 2019 – Self-administered daily vaginal swabs collected within 1 hour after sex can detect exposure to HIV

Ways to measure exposure to HIV could be important in helping identify those at the greatest risk of acquiring the virus, improving the design of future HIV prevention efficacy trials and public health interventions. Read more >


SEATTLE – JUNE 6, 2018 – South Africa gets update on large-scale HIV vaccine efficacy trials

The HVTN will join study participants, communities and in-country partners to talk about its four large-scale HIV vaccine efficacy clinical trials that are fully enrolled or nearing full enrollment. Read more >


SEATTLE – FEBRUARY 2, 2019 – Mind the Gap: The Burden of HIV Among Racial and Ethnic Minority Groups and Their Participation in Preventive HIV Vaccine Clinical Trials

An analysis conducted by the HIV Vaccine Trials Network (HVTN) observed an overall increase in the proportion of racial and ethnic minorities enrolled in Phase 1 and Phase 2A preventive HIV vaccine clinical trials in the United States between 2002 and 2016 compared to 1988 to 2002. The findings were published on December 5, 2018 in Public Health Reports. Read more >


SEATTLE – DECEMBER 20, 2018 – Study participants move HIV vaccine clinical trials forward

The HIV Vaccine Trials Network (HVTN), which is headquartered at the Fred Hutchinson Cancer Research Center, and its partners are conducting two large-scale clinical trials evaluating the safety and efficacy of experimental HIV vaccine regimens as part of a global response to the HIV and AIDS epidemic. Read more >


SEATTLE – NOVEMBER 30, 2018 – 15th Annual Stronger Together World AIDS Day breakfast

The HIV Vaccine Trials Network (HVTN), headquartered at Fred Hutchinson Cancer Research Center, joined stakeholders Friday morning at the Embassy Suites in Seattle for the 15th annual Stronger Together: World AIDS Day breakfast to celebrate Seattle’s ongoing leadership in the fight against HIV and AIDS and to recognize World AIDS Day (December 1st). Read more >


MADRID, SPAIN – OCTOBER 24, 2018 - Serum-neutralizing antibody titers correlate strongly with protection against SHIV infection

Results from a meta-analysis combining information from a variety of nonhuman primate SHIV (simian/human immunodeficiency virus) challenge studies suggest that the concentration of neutralizing HIV antibodies in the bloodstream correlates strongly to protection against SHIV infection. Read more >


MADRID, SPAIN – OCTOBER 24, 2018 - DNA vaccines hold great promise for HIV prevention research

Scientific presentations by the HIV Vaccine Trials Network (HVTN) at the HIV Research for Prevention (HIVR4P) conference showed promising early-stage clinical findings that advance the development of DNA vaccines to prevent HIV infection. Read more >


MADRID, SPAIN – OCTOBER 23, 2018 - Gut microbiome may impact HIV vaccine immune responses

Preliminary evidence presented at the HIV Research for Prevention (R4P) Conference in Madrid, Spain suggests that the composition of the human gut microbiome may inform how well an experimental HIV vaccine can elicit an immune response. Read more >


SEATTLE - OCTOBER 19, 2018 - Antibody Mediated Prevention (AMP) Studies fully enrolled & HVTN and HPTN researchers converge at R4P Conference – Madrid, Spain (October 2125, 2018)

The precedent-setting AMP Studies--the most advanced clinical trials to test whether an antibody can prevent HIV infection in people--are fully enrolled. 

The pair of Phase 2b clinical trials run by the HIV Vaccine Trials Network (HVTN), which is headquartered at Fred Hutchinson Cancer Research Center, and the HIV Prevention Trials Network (HPTN) have enrolled 4,625 participants who are at risk for HIV infection from communities in the United States, Brazil, Peru, Switzerland, and sub-Saharan Africa. Read more >


SEATTLE – OCTOBER 08, 2018 – HVTN investigates ability of mobile technology to enhance data accuracy and completeness

An HIV Vaccine Trials Network (HVTN)-funded pilot study was conducted in South Africa to test the development and implementation of a basic mobile phone-based tool to collect data from adult participants enrolled in a phase 1/2a, randomized, controlled double-blind trial called HVTN 108. Read more >

AMSTERDAM – JULY 24, 2018 – Moving toward a much needed effective HIV vaccine

Developing an effective HIV vaccine is the “key step forward” we have been pursuing as a global community to halt one of humankind’s most formidable foes. Read more >

AMSTERDAM – JULY 24, 2018 – Proactive planning: the potential benefits of an HIV vaccination campaign – a modeling study

Researchers used a dynamic economic mathematical model to show that five-dose series HIV vaccine campaigns rolled out every two years, in the country with the highest number of daily new HIV infections (South Africa), would  provide great health benefits and be potentially cost-effective. Read more >

SEATTLE – JUNE 28, 2018 - Spirit of Nelson Mandela is still alive - clinical trial site in Eastern Cape, South Africa opens its doors

The Nelson Mandela Academic Clinical Research Unit (NeMACRU) in Mthatha, South Africa became part of a network of clinical trial sites that are conducting the largest Phase 2b/3 HIV vaccine efficacy clinical trial in the country. Read more >

SEATTLE – JUNE 26, 2018 – HVTN 100 clinical trial findings advance HIV vaccine research and development

An HIV vaccine regimen tested in an early-phase clinical trial elicited robust immune responses that appeared to be stronger than those observed in a landmark 2009 study showing that a vaccine can protect people from HIV infection.  These findings from the ongoing Phase I/II HVTN 100 study were published on June 10 in Lancet HIV. Read more >

SEATTLE — May 24, 2018 — Investigators assess relationship between substance use and retention in 10 phase 1 preventive HIV vaccine clinical trials

Neither frequency of alcohol use, binge drinking, marijuana, nor other drug use negatively impacts retention and adherence rates in phase I clinical trials of preventive HIV vaccines. These were the findings revealed in a meta-analysis performed by an HIV Vaccine Trials Network (HVTN) Research and Mentorship Program (RAMP) scholar to assess the patterns of substance use among enrolled participants, and the impact substance use has on retention in phase 1 preventive HIV vaccine clinical trials. Read more >